Form 8-K - Current report:
SEC Accession No. 0001193125-26-258366
Filing Date
2026-06-05
Accepted
2026-06-05 07:05:17
Documents
15
Period of Report
2026-06-02
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d156701d8k.htm   iXBRL 8-K 34257
2 EX-10.1 d156701dex101.htm EX-10.1 21481
3 EX-10.2 d156701dex102.htm EX-10.2 50425
4 EX-99.1 d156701dex991.htm EX-99.1 14468
8 GRAPHIC g156701g69i94.jpg GRAPHIC 4523
  Complete submission text file 0001193125-26-258366.txt   268109

Data Files

Seq Description Document Type Size
5 XBRL TAXONOMY EXTENSION SCHEMA mcrb-20260602.xsd EX-101.SCH 3194
6 XBRL TAXONOMY EXTENSION LABEL LINKBASE mcrb-20260602_lab.xml EX-101.LAB 17232
7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE mcrb-20260602_pre.xml EX-101.PRE 10821
18 EXTRACTED XBRL INSTANCE DOCUMENT d156701d8k_htm.xml XML 3507
Mailing Address 200 SIDNEY STREET CAMBRIDGE MA 02139
Business Address 200 SIDNEY STREET CAMBRIDGE MA 02139 617 945 9626
Seres Therapeutics, Inc. (Filer) CIK: 0001609809 (see all company filings)

EIN.: 274326290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37465 | Film No.: 261066848
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)